News Sentiment

PRAX sentiment intelligence

Praxis Precision Medicines Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 53 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 324.99 Week of 10 Jul 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

81/100 classification confidence.

Company focus 45

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+2.0% over one week, +21.9% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Positive

Should Praxis–Remagine Transdermal Patch Collaboration and FDA Review Extension Reshape PRAX Pipeline Expectations?

Market Reaction

Balanced read

64/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 81/100 classification
One-week reaction 2.0% Price confirming higher
Trend fit Trend inactive 21.9% over four weeks
Fair value 207.6% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 16
Neutral 32
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 45
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 10
Market source 9
TradingView 5
simplywall.st 5
Investing.com 4
MT Newswires 4
Simply Wall Street 3
GlobeNewswire 3

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 10
Analyst action 9
Deals and strategy 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 53
Simply Wall Street Direct company coverage

Should Praxis–Remagine Transdermal Patch Collaboration and FDA Review Extension Reshape PRAX Pipeline Expectations?

Praxis Precision Medicines' collaboration with Remagine Labs to develop a transdermal patch for ulixacaltamide and the FDA's three-month extension for relutrigine's NDA review are significant developments for the company. These events could positively influence the perception of

Tone
Positive 64/100
Event
Market update
Published
16 Jul 2026 03:40
Source
Simply Wall Street
Market source Direct company coverage

Praxis Precision Medicines (PRAX) Enters Into Licensing and Research Collaboration With Remagine Labs

Praxis Precision Medicines Inc. (PRAX) has announced a research partnership and license agreement with Remagine Labs to develop an iontophoretic transdermal patch for ulixacaltamide delivery, a T-type calcium channel inhibitor for essential tremor. This collaboration aims to leve

Tone
Positive 67/100
Event
Deals and strategy
Published
15 Jul 2026 10:01
Source
Market source
Investing.com Direct company coverage

Piper Sandler reiterates Praxis Precision Medicines stock rating

Piper Sandler has reiterated an Overweight rating and $1,200 price target for Praxis Precision Medicines (NASDAQ:PRAX), citing the company's strong financial position and high (95%) probability of regulatory success for ulixacaltamide. The company has two PDUFA dates soon and ant

Tone
Neutral 50/100
Event
Analyst action
Published
13 Jul 2026 13:09
Source
Investing.com
Investing.com Direct company coverage

Goldman Sachs initiates Praxis Precision Medicines stock coverage with buy rating

Goldman Sachs has initiated coverage of Praxis Precision Medicines (NASDAQ:PRAX) with a Buy rating and a price target of $447.00. The biotechnology company has two potential drug approvals expected by January 2027, including ulixacaltamide for essential tremor and relutrigine for

Tone
Positive 72/100
Event
Analyst action
Published
13 Jul 2026 10:09
Source
Investing.com
Simply Wall Street Direct company coverage

Can Praxis Precision Medicines (PRAX) Merit A Higher Valuation As It Expands Ulixacaltamide Delivery?

Praxis Precision Medicines (PRAX) has partnered with Remagine Labs to develop a transdermal patch for ulixacaltamide, aiming to expand its essential tremor program beyond oral delivery. Despite recent stock price momentum and a reported undervaluation narrative suggesting a fair

Tone
Positive 72/100
Event
Market update
Published
10 Jul 2026 16:09
Source
Simply Wall Street
Moomoo Direct company coverage

Praxis Precision Medicines Seen Having Greater Commercial Upside for Relutrigine, RBC Says

RBC Capital Markets believes Praxis Precision Medicines' relutrigine has greater commercial potential in essential tremor (ET) than in movement disorders. The analyst firm initiated coverage with an "Outperform" rating and a $10 price target, projecting peak sales of $1.5 billion

Tone
Positive 72/100
Event
Analyst action
Published
10 Jul 2026 15:41
Source
Moomoo
Investing.com Nigeria Direct company coverage

Form 4 Praxis Precision Medicines Inc For: 8 July By Investing.com

This article reports on the filing of Form 4 for Praxis Precision Medicines Inc. on July 8. It indicates that the document is available for review, likely detailing insider transactions for the company.

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 22:17
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Praxis (PRAX) CEO Marcio Souza gifts 23,121 shares, retains 56,495

Praxis Precision Medicines, Inc. CEO Marcio Souza reported gifting a total of 23,121 shares of company common stock through bona fide gifts to the Souza 2026 Trust. These transactions, which are not market sales, included 2,600 shares previously held indirectly and 20,521 directl

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:41
Source
Stock Titan
GlobeNewswire Direct company coverage

Praxis Precision Medicines and Remagine Labs Announce Strategic Collaboration to Develop Transdermal Ulixacaltamide for Essential Tremor

Praxis Precision Medicines and Remagine Labs have announced a strategic collaboration to develop an iontophoretic transdermal patch for ulixacaltamide, Praxis's lead essential tremor (ET) therapy. This aims to expand the addressable market for the drug, which recently had its New

Tone
Positive 95/100
Event
Market update
Published
08 Jul 2026 07:41
Source
GlobeNewswire
Simply Wall Street Direct company coverage

Is Ulixacaltamide Patch Collaboration and Equity Stake Altering The Investment Case For Praxis (PRAX)?

Praxis Precision Medicines has entered a collaboration with Remagine Labs to develop a transdermal patch for ulixacaltamide to treat essential tremor, alongside an equity investment. This partnership aims to expand the delivery options for its lead asset and potentially enhance i

Tone
Neutral 50/100
Event
Deals and strategy
Published
08 Jul 2026 07:39
Source
Simply Wall Street
Stock Titan Direct company coverage

Praxis (PRAX) teams with Remagine Labs on transdermal ulixacaltamide for essential tremor

Praxis Precision Medicines (PRAX) has partnered with Remagine Labs to develop an iontophoretic transdermal patch for delivering ulixacaltamide to treat essential tremor. This collaboration aims to broaden the patient population for ulixacaltamide, complementing Praxis's existing

Tone
Positive 65/100
Event
Market update
Published
07 Jul 2026 20:40
Source
Stock Titan
GuruFocus Direct company coverage

Praxis Precision (PRAX) Partners with Remagine Labs for Innovati

Praxis Precision Medicines Inc (PRAX) has partnered with Remagine Labs to develop an innovative transdermal patch for ulixacaltamide, a treatment for essential tremor. This collaboration aims to enhance drug delivery through iontophoresis, improving upon existing oral treatments.

Tone
Positive 58/100
Event
Market update
Published
07 Jul 2026 13:11
Source
GuruFocus
Stock Titan Direct company coverage

Praxis bets on skin patch for essential tremor drug

Praxis Precision Medicines and Remagine Labs have announced a strategic collaboration to develop an iontophoretic transdermal patch for ulixacaltamide, an essential tremor (ET) drug that has received FDA Breakthrough Therapy Designation. This partnership aims to expand the treatm

Tone
Positive 71/100
Event
Deals and strategy
Published
07 Jul 2026 12:11
Source
Stock Titan
Market source Direct company coverage

Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Praxis Precision Medicines, Inc. announced that its Board's Compensation Committee granted restricted stock unit awards for 951 shares of common stock to five new non-executive employees on July 1, 2026. These inducement grants were made under the company's 2024 Inducement Plan,

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 05:41
Source
Market source
Stock Titan Direct company coverage

Praxis Precision (NASDAQ: PRAX) replaces EY with KPMG as auditor

Praxis Precision Medicines, Inc. announced that its Audit Committee dismissed Ernst & Young LLP (EY) and engaged KPMG LLP as its independent registered public accounting firm, effective June 29, 2026. The company stated that there were no disagreements with EY on accounting princ

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:10
Source
Stock Titan
Stock Titan Direct company coverage

Praxis uses inducement plan to grant 951 shares to five hires

Praxis Precision Medicines, Inc. announced the grant of 951 restricted stock units (RSUs) to five new non-executive employees under its 2024 Inducement Plan. These RSUs, designed to attract and retain talent, will vest in four equal annual installments, in accordance with Nasdaq

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 20:10
Source
Stock Titan
TradingView Direct company coverage

Price to sales forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX

This article provides access to the "Price to sales forward" financial data for Praxis Precision Medicines, Inc. (NASDAQ: PRAX) on TradingView. It highlights the company's financial overview within the pharmaceuticals sector and indicates that the market is currently closed with

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 04:22
Source
TradingView
TradingView Direct company coverage

Price to book forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX

This article provides financial information for Praxis Precision Medicines, Inc. (NASDAQ: PRAX), specifically focusing on its Price to Book Forward metric. It indicates that the company's financial data is provided by reputable sources like ICE Data Services and FactSet. The cont

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 19:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Praxis Precision Medicines, Inc. – NASDAQ:PRAX

This article focuses on the "Price to earnings forward" metric for Praxis Precision Medicines, Inc. (NASDAQ: PRAX). It appears to be a financial data page from TradingView, indicating that the market for PRAX was closed with no trades at the time of viewing.

Tone
Neutral 50/100
Event
Earnings
Published
30 Jun 2026 05:13
Source
TradingView
Investing.com Direct company coverage

Praxis Precision Medicines stock falls on FDA review delay

Praxis Precision Medicines (NASDAQ:PRAX) shares fell 7% after the FDA extended its review period for relutrigine by three months. The new PDUFA target action date is December 27, 2026, due to the company submitting additional sensitivity analyses of existing clinical data. Relutr

Tone
Negative 29/100
Event
Analyst action
Published
30 Jun 2026 05:10
Source
Investing.com
GlobeNewswire Direct company coverage

Praxis Precision Medicines Announces Extension Period for

Praxis Precision Medicines announced that the FDA has extended the review period for its New Drug Application (NDA) for relutrigine by three months, setting an updated PDUFA date of December 27, 2026. This extension allows for additional time to review new sensitivity analyses of

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 04:10
Source
GlobeNewswire
Stock Titan Direct company coverage

FDA extends Praxis (NASDAQ: PRAX) relutrigine review deadline to Dec 27, 2026

The FDA has extended the review period for Praxis Precision Medicines' New Drug Application (NDA) for relutrigine by three months, moving the PDUFA target action date to December 27, 2026. This extension occurred because Praxis submitted additional sensitivity analyses of existin

Tone
Negative 39/100
Event
Analyst action
Published
29 Jun 2026 21:10
Source
Stock Titan